Redoxis: Specialists in Preclinical Drug Development
Redoxis is a service company in preclinical drug development with a focus on inflammation and autoimmunity. The company provides fully customized studies for each client – whether a small biotech developer, a large pharmaceutical company, or an academic research group.
“Our strength lies in our niche focus. We are fast, flexible, and both customer- and project-oriented, always doing what is best for the project,” says Redoxis CEO Malin Hultqvist.
“We do not provide standard solutions; instead, we draw on our broad portfolio of models and tailored analyses to deliver unique and reliable results.”
Redoxis was founded in 2007 as an R&D spin-off from Lund University, established as an independent company with a focus on preclinical development of small molecules targeting inflammation and autoimmune diseases.
“Over time, we began receiving requests from pharmaceutical companies to test potential new drugs in our models, which marked the start of the service company we are today.”
Focus on CRO services
When Malin Hultqvist became CEO in 2016, she positioned Redoxis as a CRO-focused service company. Since then, the service portfolio has expanded, and the number of employees has grown from 5 to just over 20. The company provides preclinical in vivo and in vitro models, including pharmacological efficacy studies, functional assays, mechanism of action (MoA) evaluation, ex vivo ranking, pharmacokinetic (PK) studies, biomarker identification, and biomarker analyses.
“The majority of our revenue comes from in vivo assignments, where we evaluate efficacy in autoimmune disease models. We collaborate with several companies in our immediate network, including here at Medicon Village, to provide customized package solutions for our clients,” says Malin Hultqvist.
“An important part of our success is being attentive to our clients’ needs and quickly adapting our services and models to deliver what they require. We are continuously adding new models and types of analyses to our portfolio.”
Redoxis has been part of Medicon Village – Scandinavia’s largest research park – since its opening in 2012, relocating to larger premises in step with the company’s steady organic growth. In the summer of 2024, the company moved into Medicon Village’s new state-of-the-art laboratory building for advanced research and medical development – a key step in Redoxis’ continued growth.
“With a fully equipped immunology laboratory, we can perform most in vitro services related to inflammation and have increased capacity to manage studies, including cell culture projects. Here, we can conduct everything from Luminex assays to flow cytometry,” Hultqvist explains.
“Our new facilities are purpose-built to meet our needs, with spacious areas that allow us to grow and run several projects in parallel. Having everything under one roof also enables us to build a stronger company culture.”
New markets
The new facilities also create entirely new opportunities for client engagement and visits, including meetings and customer events. Historically, Redoxis’ client base has been companies active in the Nordics and Northern Europe, but in recent years the company has expanded into new markets in Asia and North America.
“We have many repeat clients and frequently gain new ones through our extensive network. We also participate actively in industry conferences and meetings to connect with new partners."
"This summer, for example, we attended the BIO International Convention in Boston – one of the largest and most influential partnering events in the industry – where we met several potential clients,” says Hultqvist.
